Search Articles

Found 1,803 articles

  • NorthX Biologics appoints industry veterans to its

    NorthX Biologics appoints industry veterans to its board of directors

    • 14 Jun 2022
    • Editor

    Sweden-based NorthX Biologics (“NorthX”), which focuses on process development and GMP manufacture of advanced biological drugs, has announced the appointments of Lotta Ljungqvist, Richard Bergström, Mathias Uhlén and Lars Backsell to its board of directors.

  • Anjarium Biosciences appoints Stephen Yoo, MD as C

    Anjarium Biosciences appoints Stephen Yoo, MD as Chief Executive Officer

    • 14 Jun 2022
    • Editor

    Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announced the appointment of Stephen Yoo, MD as the Company’s Chief Executive Officer (CEO).

  • Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally

    Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over

    • 14 Jun 2022
    • Editor

    Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over.

  • Top Pharma Recruiters Advertising in June

    Top Pharma Recruiters Advertising in June

    • 13 Jun 2022
    • Nola Cadman

    Here are the top Pharma and Life Science recruitment organisations advertising in June on PharmiWeb.jobs

  • NOXXON Enters Into Collaboration With US National

    NOXXON Enters Into Collaboration With US National Cancer Institute to Characterize Effects of Lead Compounds on Brain Tumors

    • 13 Jun 2022
    • Editor

    NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today it has entered into a material transfer agreement with the U.S. National Cancer Institute (NCI), of the National Institutes of Health (NIH).

  • Focus On: GLS Hub

    Focus On: GLS Hub

    • 13 Jun 2022
    • Lucy Walters

    With over 15 years of experience across their senior leadership team, The Global Life Science Hub provides functional services and consulting with a solid mission to accelerate, strengthen and enhance global clinical trials.

  • Gerresheimer partners with MedTech start-up Adaman

    Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease

    • 13 Jun 2022
    • Editor

    Gerresheimer AG and the Finnish MedTech start-up Adamant Health Oy partner up to develop a life-changing solution for millions of people worldwide suffering from Parkinson’s disease.

  • Network Pharma: Working in and Around #MedComms

    Network Pharma: Working in and Around #MedComms

    • 10 Jun 2022
    • Editor

    Organised by Network Pharma, this is an exciting and informative in-person meeting for those wanting to learn more about careers in and around #MedComms.

  • Weekly Life Science News Round Up: 6th – 10th June

    Weekly Life Science News Round Up: 6th – 10th June

    • 10 Jun 2022
    • Lucy Walters

    A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Devices sectors from 6th-10th June.

  • Focus On: Santen Cell & Gene

    Focus On: Santen Cell & Gene

    • 10 Jun 2022
    • Editor

    Already experts in the area of ophthalmology, Santen decided to harness the potential of cell and gene therapies (CGTs) to address unmet needs and change the lives of patients living with inherited retinal disorders (IRDs).

  • Kinarus Therapeutics Announces Name Change and Com

    Kinarus Therapeutics Announces Name Change and Commences Trading on the SIX Swiss Exchange under ticker “KNRS”

    • 10 Jun 2022
    • Editor

    Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory, and ophthalmic diseases, announced that it has changed its name and that trading of its shares on the SIX Swiss exchange will continue today under the new ticker symbol KNRS. Kinarus AG’s board and executive management now have full responsibility for leadership of Kinarus Therapeutics.

  • Australia's Global Talent Visa - Fact Sheet

    Australia's Global Talent Visa - Fact Sheet

    • 9 Jun 2022
    • Editor

    The Global Talent Independent (GTI) Program is a program designed to attract skilled migrants at the top future-focussed fields to Australia. The program provides a fast-tracked pathway to permanent residency for highly-skilled individuals.

  • Webinar Schedule

    Webinar Schedule

    • 9 Jun 2022
    • Editor

    PharmiWeb now runs regular webinars where we discuss some of the key issues that talent acquisition professionals in the life science space should be focusing on. Take a look at our webinar schedule to see what's coming up, and register now for future sessions.

  • 12 Ways to Optimise Your Work from Home Space

    12 Ways to Optimise Your Work from Home Space

    • 9 Jun 2022
    • Editor

    A 2021 Mercer survey reported that 87% of life science companies were planning to offer part-time remote working models in the future. In 2022, remote working opportunities across the industry are continuously rising, with companies such as IQVIA, Worldwide Clinical Trials and Syneos Health advertising homeworking roles across the globe. To make homeworking work for you, we’ve outlined 12 things you can do to optimise your work from home space.

  • Thermo Fisher Scientific's Clinical Research Busin

    Thermo Fisher Scientific's Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year

    • 9 Jun 2022
    • Editor

    The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.

  • CureVac Accelerates Oncology Strategy with Acquisi

    CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

    • 9 Jun 2022
    • Editor

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

  • Worldwide Clinical Trials Opens Multimillion Dolla

    Worldwide Clinical Trials Opens Multimillion Dollar Bioanalytical Center of Excellence Supporting Early Phase Development

    • 8 Jun 2022
    • Editor

    Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), has announced that it expanded its early phase clinical trial capabilities by opening its Bioanalytical Center of Excellence – a larger state-of-the-art lab in Austin, Texas. This investment builds on Worldwide’s recent addition of three key leadership roles and enables the company to optimally support preclinical and early phase development.

  • DFE Pharma Appoints New Global HR Director to Furt

    DFE Pharma Appoints New Global HR Director to Further Invest in Team and Add Value

    • 8 Jun 2022
    • Editor

    DFE Pharma, a global leader in pharma-, biopharma-and nutraceutical excipient solutions, has appointed Marie-Louise Mans as Global Human Resources (HR) Director, joining as a member of the Leadership Team.

  • FDA Advisory Committee Recommends Emergency Use Au

    FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

    • 8 Jun 2022
    • Editor

    Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 21 to 0, with one abstention,

  • Evusheld significantly prevented COVID-19 disease

    Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

    • 8 Jun 2022
    • Editor

    Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically significant protection against progression to severe COVID-19 or death from any cause compared to placebo, with treatment with Evusheld earlier in the disease course leading to more favourable outcomes.1